At week zero the patients will be provided with information leaflets about the study and the process will be explained and questions answered. Those patients giving informed consent will be screened for baseline measurements including the CCUK fatigue score, in addition to completing the other questionnaires outlined in the methodology above. Baseline blood and stool samples will be taken to assess disease activity. Patients deemed to have active disease will be excluded from the rest of the study and their medical management optimised in line with local and national guidelines. Those patients meeting the inclusion criteria will be provided with activity diaries and asked to complete them over the following 4 weeks. All patients will have their baseline data analysed to study any association between fatigue scores and disease activity (as measured by HBI/Mayo score, CRP, FC), quality of life (as measured by SF36 & S-IBDQ), anxiety and depression (HAD) or somatisation (PHQ15).